PYC Therapeutics (ASX:PYC) received all regulatory approvals to start human trials of its drug candidate for polycystic kidney disease, the company said in a Monday Australian bourse filing.

Polycystic kidney disease is a life-changing disease where multiple cysts form throughout a patient's kidney that increase in size over time.

Dosing of patients in the single ascending dose study is expected to be completed in about 12 months with a budgeted cost of AU$10 million, per the filing. The primary endpoint is treatment-emergent adverse events and treatment-emergent serious adverse events.

The initial human safety and efficacy data are anticipated within the year, the filing added.

Company shares were up nearly 3% in recent Monday trade.